8432.TWO tsh biopharmoration Ltd
- Market cap
- TWD 2.25B
- P/E
- 13.5x
- P/B
- 1.64x
- ROE
- 12.0%
- Dividend yield
- 3.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 8432.TWO undervalued?
Graham number8432.TWO trades 0.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
tsh biopharmoration Ltd fundamental analysis
No fundamental analysis for tsh biopharmoration Ltd yet.
tsh biopharmoration Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About tsh biopharmoration Ltd
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid biopsy test designed for MRD detection and surveillance in stage I-III solid tum…
Full company profiletsh biopharmoration Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
tsh biopharmoration Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 486M | 516M | 508M | 448M | 413M | 741M | 811M | 1.12B | 1.34B | 1.23B |
| Gross Profit | 317M | 334M | 315M | 285M | 247M | 390M | 400M | 583M | 681M | 680M |
| Operating Income | 70.9M | 56.1M | 56.2M | 77.2M | 61.5M | 85.0M | 74.8M | 171M | 219M | 250M |
| EBITDA | 76.8M | 61.7M | 113M | 86.8M | 71.3M | 107M | 97.4M | 203M | 262M | 292M |
| Net Income | 65.0M | 57.8M | 85.3M | 61.6M | 47.1M | 61.9M | 62.0M | 113M | 139M | 169M |
| EPS | 1.69 | 1.50 | 2.22 | 1.60 | 1.23 | 1.61 | 1.61 | 2.95 | 3.63 | 4.40 |
| Balance Sheet | ||||||||||
| Total Assets | 1.28B | 1.22B | 1.26B | 1.23B | 1.17B | 1.44B | 1.40B | 1.84B | 1.95B | 2.03B |
| Total Liabilities | 135M | 99.4M | 139M | 103M | 85.8M | 222M | 134M | 219M | 234M | 349M |
| Shareholders' Equity | 1.15B | 1.12B | 1.12B | 1.13B | 1.08B | 1.14B | 1.11B | 1.39B | 1.44B | 1.41B |
| Cash & Short-term Investments | 395M | 216M | 224M | 726M | 733M | 816M | 772M | 588M | 465M | 619M |
| Total Debt | - | - | - | 10.3M | 5.01M | 63.9M | 7.84M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 81.1M | 62.6M | 88.6M | 11.6M | 68.7M | 34.4M | 33.9M | 184M | 140M | 420M |
| Capital Expenditure | 4.57M | 5.89M | 3.00M | 2.38M | 382K | 18.7M | 5.56M | 2.74M | 10.4M | 9.29M |
| Free Cash Flow | 76.6M | 56.6M | 85.5M | 9.23M | 68.3M | 15.6M | 28.3M | 181M | 129M | 411M |
| Ratios | ||||||||||
| ROE | 5.7% | 5.2% | 7.6% | 5.5% | 4.3% | 5.4% | 5.6% | 8.1% | 9.7% | 12.0% |
| ROA | 5.1% | 4.7% | 6.8% | 5.0% | 4.0% | 4.3% | 4.4% | 6.1% | 7.1% | 8.3% |
| Net Profit Margin | 13.4% | 11.2% | 16.8% | 13.7% | 11.4% | 8.4% | 7.6% | 10.1% | 10.4% | 13.7% |
| Debt to Equity | - | - | - | 0.01x | 0.00x | 0.06x | 0.01x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
tsh biopharmoration Ltd dividends
- Dividend yield
- 3.61%
- Forward dividend
- 2.61 TWD
- Payout ratio
- 58.5%
- Ex-dividend date
- Jun 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 81.4M | 2.12 | 58.5% |
| 2024 | TWD 49.2M | 1.28 | 43.5% |
| 2023 | TWD 61.4M | 1.60 | 99.1% |
| 2022 | TWD 57.6M | 1.50 | 93.1% |
| 2021 | TWD 69.1M | 1.80 | 146.7% |
| 2020 | TWD 69.1M | 1.80 | 112.3% |
| 2019 | TWD 61.4M | 1.60 | 72.0% |
| 2018 | TWD 80.6M | 2.10 | 139.5% |
| 2017 | TWD 119M | 3.10 | 183.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.1:1 on Aug 28, 2013.
Who owns tsh biopharmoration Ltd
- Insiders 65.64%
- Institutions 0.00%
- Public & others 34.36%
- Shares outstanding 38.4M
- Free float 14.7M
tsh biopharmoration Ltd company profile
- Company name
- tsh biopharmoration Ltd
- Ticker
- 8432.TWO
- ISIN
- TW0008432006
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- No. 3-1 Yuanqu Street, Taipei, Taiwan, 11503
- Phone
- 886 2 2655 8525
- Website
- tshbiopharm.com
About tsh biopharmoration Ltd
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid biopsy test designed for MRD detection and surveillance in stage I-III solid tumor patients; AlphaLiquid 100, a liquid biopsy test designed for patients with advanced solid cancers; AlphaLiquid HRR, AlphaSolid, and AlphaSolid HRR, a tissue biopsy test designed for patients with advanced solid cancers. The company was founded in 2000 and is headquartered in Taipei, Taiwan. TSH Biopharm Corporation Limited operates as a subsidiary of TTY Biopharm Company Limited.
tsh biopharmoration Ltd management
6- Ms. Sze-Yuan YangPresident
- Mr. Jung-Liang KaoSenior Division Director of Finance Division & CFO
- Ms. Chen-Ju KanSenior Manager of the Accounting Department
- Mr. Yu-Chung WuSenior Director of Sales
- Mr. Chuan-Hsu ChenSenior Director of Marketing
- Mr. Hsin-Young LiuCompany Secretary